sb 203580 has been researched along with Dengue in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blasco, F; Fu, Y; Hervé, M; Seah, PG; Shi, PY; Yip, A | 1 |
| Medin, CL; Rothman, AL | 1 |
2 other study(ies) available for sb 203580 and Dengue
| Article | Year |
|---|---|
Modulation of inflammation and pathology during dengue virus infection by p38 MAPK inhibitor SB203580.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Capillary Permeability; Cell Line; Chemokine CCL5; Cricetinae; Culicidae; Dengue; Dengue Virus; Enzyme Inhibitors; Hematocrit; Humans; Imidazoles; Inflammation; Interleukin-8; Lymphopenia; Mice; p38 Mitogen-Activated Protein Kinases; Pyridines; Tumor Necrosis Factor-alpha | 2014 |
Cell type-specific mechanisms of interleukin-8 induction by dengue virus and differential response to drug treatment.
Topics: Cell Line; Cell Line, Tumor; Dengue; Dengue Virus; Dexamethasone; DNA, Recombinant; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Gene Expression; Genes, Reporter; Glucocorticoids; Humans; Imidazoles; Interleukin-8; Luciferases; NF-kappa B; Phosphodiesterase Inhibitors; Pyridines; Rolipram; Transcription Factor AP-1 | 2006 |